- Home
- CAN vs ALT Comparison
CAN vs ALT Comparison
Compare CAN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | ALT |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.9M | 421.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CAN | ALT |
|---|---|---|
| Price | $0.30 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.21 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 10.9M | 4.8M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $0.26 | $2.56 |
| 52 Week High | $2.22 | $6.44 |
Technical Indicators
Market Signals| Indicator | CAN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 50.68 |
| Support Level | N/A | $2.87 |
| Resistance Level | $0.38 | $3.15 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.68 | 34.85 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.